tbuckley/cabot-search huggingface dataset:
The Hamman Sign: A Case Report With Audio Recording
Authors: Gabby Reijnders, Stijn de Ridder
Journal: Annals of Internal Medicine (2019)

Letters17 March 2020The Hamman Sign: A Case Report With Audio RecordingGabby Reijnders, MD and Stijn de Ridder, MDGabby Reijnders, MDRadboud University Medical Centre, Nijmegen, the Netherlands (G.R.)Search for more papers by this author and Stijn de Ridder, MDSt. Anna Hospital, Geldrop, the Netherlands (S.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0428 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Louis Hamman, MD, is credited with the first description of “peculiar sounds [that] consist of crackles, bubbles or churning sounds . . . over the lower portion of the sternum and to the left of the sternum or near the apex of the heart” (1). Others have described the sounds as crunching, rasping, clicking, or whooping in quality. The Hamman sign was originally associated with pneumomediastinum, but it since has been linked to left-sided pneumothorax.Objective: To remind clinicians of the diagnostic value of recognizing the Hamman sign.Case Report: We were involved in the care of a 68-year-old ...References1. Hamman L. Mediastinal emphysema. The Frank Billings lecture. JAMA. 1945;128:1-6. CrossrefGoogle Scholar2. Lister WA. A case of pericardial knock associated with spontaneous pneumothorax. Lancet. 1928;211.5468:1225-6. CrossrefGoogle Scholar3. Chapman JS. Spontaneous irruption of air from the lung. I. Pneumomediastinum. Am J Med. 1955;18:547-56. [PMID: 14361439] CrossrefMedlineGoogle Scholar4. Roelandt J, Willems J, van der Hauwaert LG, et al. Clicks and sounds (whoops) in left-sided pneumothorax. Clinical and phonocardiographic study. Dis Chest. 1969;56:31-6. [PMID: 5795857] CrossrefMedlineGoogle Scholar5. Baumann MH, Sahn SA. Hamman's sign revisited. Pneumothorax or pneumomediastinum? Chest. 1992;102:1281-2. [PMID: 1395785] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Radboud University Medical Centre, Nijmegen, the Netherlands (G.R.)St. Anna Hospital, Geldrop, the Netherlands (S.D.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0428.This article was published at Annals.org on 12 November 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe clicking chest: what exactly did Hamman hear? A case report of a left-sided pneumothorax 17 March 2020Volume 172, Issue 6Page: 435-436KeywordsChronic obstructive pulmonary diseaseComputed axial tomographyEmphysemaHeartPercutaneous coronary interventionPulmonary diseasesResearch laboratoriesSternumThoraxVomiting ePublished: 12 November 2019 Issue Published: 17 March 2020 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study
Authors: Paige L Williams, Cenk Yildirim, Ellen G Chadwick, Russell B Van Dyke, Renee Smith, Katharine F Correia, Alexandria DiPerna, George R Seage, Rohan Hazra, Claudia S Crowell
Journal: The Lancet HIV (2019)
First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
Authors: Scott R. Solomon, Aziz Nazha, Stephen A. Strickland, Roland B. Walter, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, Pawel Chrom, Simone Baldini, Krzysztof Brzózka, Angela Capriati, Andrea Pellacani, Farhad Ravandi
Journal: Blood (2019)
Retrospective Review of Patients with Large Granular Lymphocyte (LGL) Leukemia in a Single Institution over a Period of 11 Years
Authors: Kulsum Bano, Manojna Konda, Dinesh Atwal, Richa Parikh, Aneesha Ananthula, Anusha Jillella, Aasiya Matin, Appalanaidu Sasapu
Journal: Blood (2019)
A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study
Authors: Hui Liu, ZhiTao Gu, Bo Qiu, Frank C. Detterbeck, Anja C. Roden, Enrico Ruffini, Meinoshin Okumura, Nicolas Girard, YangWei Xiang, Yuan Liu, ZhiCheng Du, YuanTao Hao, JianHua Fu, Peng Zhang, LieWen Pang, KeNeng Chen, Yun Wang, ZhenTao Yu, Teng Mao, WenTao Fang
Journal: Journal of Thoracic Oncology (2019)
Diphtheria in an Immunized Community
Authors: E. Carlinfanti
Journal: BMJ (1947)

Co-operation of Obstetricians and Paediatricians SIR,-Reference has been made in recent numbers of the -Journal to the desirability of obstetricians and paediatricians -co-operating in their joint interest in the newborn infant.I should like to emphasize the value of such an experience in the light of the practice in the Belfast Medical School.Every month the obstetricians and paediatricians of the maternity hospitals in Belfast meet to review the obstetric and paediatric problems of the previous month.The audience includes, in addition, the pathologist, anaesthetist, obstetric and paediatric registrars and tutors, senior and junior R.M.O.s, and the appropriate members of the nursing staff.Representatives *of the Ministry of Health and of the Belfast Corporation Maternity and Infant Welfare Department also attend.The programme includes statistics of the number of births, propor- tion of caesarean and forceps deliveries, etc., data relating to maternal and infant mortality and morbidity, as well as details of stillbirths and neonatal deaths.Discussions take place on
Strategy for Identification of an Inherited Leukemia Predisposition in a 299 Patients Cohort with Tumor-Only Sequencing Data
Authors: Almudena Aguilera Díaz, Sara Palomino-Echeverria, Iria Vazquez, Beñat Ariceta, Maria Jose Larrayoz, Amagoia Mañu, Zuriñe Blasco-Iturri, Matxalen Olivares Salaverri, Maria Teresa Olave Rubio, Teresa Bernal Del Castillo, Jose J. Rifon Roca, Ana Alfonso Pierola, Felipe Prosper, Marta Fernández-Mercado, Maria Jose Calasanz
Journal: Blood (2019)
Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study
Authors: Dennis Cooper, Jackie Manago, Vimal Patel, Dale Schaar, Tracy Krimmel, Mary Kate McGrath, Anne Tyno, Roger Strair
Journal: Blood (2019)
ACTR-06. CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT
Authors: Zhong-ping Chen, Chengcheng Guo, Qun-ying Yang, Jia-wei Li, Shao-xiong Wu, Jeffrey Bacha, Gregory Johnson, John Langlands, Claire Kwan, Sarath Kanekal, Richard Schwartz, Lorena Lopez, Dennis Brown
Journal: Neuro-Oncology (2019)

Abstract Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated methylguanine DNA-methyltransferase (MGMT gene, which confers a limited response to standard of care treatment with temozolomide (TMZ) resulting in a lower survival. VAL-083 is a novel bi-functional DNA targeting agent that induces interstrand cross-links at N7-guanine, leading to DNA double-strand breaks and ultimately cell death. VAL-083 circumvents MGMT-mediated repair of the O6 guanine alkylator TMZ. A Phase 2 study has been initiated for VAL-083 in newly diagnosed MGMT unmethylated GBM. The study has 2 stages: Stage 1 is a dose-escalation and induction format to confirm the recommended dose of VAL-083 when administered concurrently with radiation therapy (RT) based on safety and tolerability. The subjects received VAL-083 at 20, 30, or 40 mg/m2/day x 3 days every 21 days along with standard radiation treatment. Stage 2 comprises an expansion phase to enroll up to 30 patients. The dose escalation stage is complete and 30 mg/m2/day of VAL-083 in combination with RT was generally safe and well-tolerated. As of 17 May, 2019, 18 patients have been enrolled. Fifteen patients have completed their prospectively planned MRI scans and had their initial assessment for tumor progression. Of these 15 patients, seven were assessed as a complete response (CR), and eight patients as having stable disease (SD). Of the remaining three patients, one died prior to their post-cycle 3 MRI and two have not been on study long enough to reach their planned post-cycle 3 MRI. As of the data cutoff, 14 of the 18 patients were still alive. Consistent with our prior experience, myelosuppression was the most common adverse event. Three dose-limiting toxicities have been reported - one at the 40 mg/m2/day and two at the 30 mg/m2/day dose. Further enrollment, safety &amp; study updates will be presented at the meeting. Clinicaltrials.gov identifier: NCT03050736.
Ketogenic diet activates protective γδ T cell responses against influenza virus infection
Authors: Emily L. Goldberg, Ryan D. Molony, Eriko Kudo, Sviatoslav Sidorov, Yong Kong, Vishwa Deep Dixit, Akiko Iwasaki
Journal: Science Immunology (2019)

Influenza A virus (IAV) infection-associated morbidity and mortality are a key global health care concern, necessitating the identification of new therapies capable of reducing the severity of IAV infections. In this study, we show that the consumption of a low-carbohydrate, high-fat ketogenic diet (KD) protects mice from lethal IAV infection and disease. KD feeding resulted in an expansion of γδ T cells in the lung that improved barrier functions, thereby enhancing antiviral resistance. Expansion of these protective γδ T cells required metabolic adaptation to a ketogenic diet because neither feeding mice a high-fat, high-carbohydrate diet nor providing chemical ketone body substrate that bypasses hepatic ketogenesis protected against infection. Therefore, KD-mediated immune-metabolic integration represents a viable avenue toward preventing or alleviating influenza disease.
ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment
Authors: Danny V Jeyaraju, Ekta Kumari, Michael Amatangelo, Chad C. Bjorklund, Chih-Chao Hsu, Anjan Thakurta
Journal: Blood (2019)
A REBALANCED HEMOSTATIC SYSTEM IN PEDIATRIC PATIENTS UNDERGOING LIVER TRANSPLANTATION : A PROSPECTIVE COHORT STUDY
Authors: Maureen Werner, Vincent E. De Meijer, Jelle Adelmeijer, Ruben H. J. De Kleine, Rene Scheenstra, Sander T. H. Bontemps, Ton Lisman, Robert J. Porte
Journal: Hepatology (2019)
CMET-37. CLINICAL UTILITY OF ENCYCLOPEDIC TUMOR ANALYSIS TO TREAT PATIENTS WITH BRAIN METASTASIS IN REFRACTORY CANCERS
Authors: Timothy Crook, Darshana Patil, Dadasaheb Akolkar, Anantbhushan Ranade, Amit Bhatt, Vineet Datta, Jatinder Bhatia, Stefan Schuster, Revati Patil, Ajay Srinivasan, Harjeet Kathuria, Rajan Datar
Journal: Neuro-Oncology (2019)

Abstract Brain metastasis in solid organ cancers is associated with adverse prognosis, which is further aggravated by limited systemic treatment options. Such patients are also often excluded from clinical trials since their poor prognosis is perceived to unfavorably impact trial outcomes and misrepresent efficacy data. We retrospectively evaluated the efficacy of treatment guided by Encyclopedic Tumor Analysis (ETA) in patients with advanced refractory malignancies and brain metastases to determine the impact on outcomes. Freshly biopsied tumor tissue (primary / lymph node / liver) and peripheral blood of patients were used for integrational multi-analyte investigations as part of ETA, which included gene mutations, gene expression, and in vitro chemosensitivity profiling of viable tumor cells. Based on ETA, patients received individualized therapy recommendations. All patients underwent a PET-CT scan as well as MRI scan prior to treatment start to determine extent of disease. All patients underwent follow-up PET-CT scans and brain MRI scans every 6–8 weeks. Of the ten patients with brain metastases, which were evaluated after receiving ETA-guided treatment, the median follow-up duration was 97 days (range 79 – 180 days) during which all ten patients remained progression-free. Median time to progression for these patients on the last (failed) line of treatment was 91 days (range 30 - 176 days). Five patients showed partial response and five patients showed stable disease while on ETA-guided treatment. During the follow-up period, all brain metastases were either stable (n=7) or had regressed (n=3), and none of the patients reported new brain lesions. Personalized ETA guided treatments imparted clinical benefit by halting disease progression in this cohort of high-risk patients who would have otherwise been considered for palliative regimens due to perceived unfavorable prognosis.
Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma
Authors: Meng Wang, Iulian Pruteanu, Adam D. Cohen, Alfred L. Garfall, Lifeng Tian, Simon F Lacey, Joseph A Fraietta, Jennifer Brogdon, Megan Davis, Vanessa E. Gonzalez, Bruce L Levine, Don L. Siegel, Michael C. Milone, Edward A. Stadtmauer, Carl H June, J. Joseph Melenhorst
Journal: Blood (2019)
Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures
Authors: Ryan M. Carr, Terra Lasho, David Marks, Ezequiel Tolosa, Luciana L Almada, Bonnie Alver, Moritz Binder, Stephanie Safgren, Isaac Horn, Kurt Berger, Abhishek A Mangaonkar, Guadalupe Belen Antelo, Giacomo Coltro, Christopher Pin, Thomas E. Witzig, Keith Robertson, Matthew T Howard, Klaus Geissler, Naseema Gangat, Ayalew Tefferi, Animesh Pardanani, Aref Al-Kali, Mark Litzow, Michelle A Elliott, Scott H. Kaufmann, Martin Fernandez-Zapico, Martin Fernandez-Zapico, Mrinal M Patnaik
Journal: Blood (2019)
TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study
Authors: Rémy Duléry, Laure Lebras, Sylvain Choquet, Roberta Di Blasi, Ahmad Kanj AL Jijakli, Laurence Heuberger, Eolia Brissot, Giorgia Battipaglia, Florent Malard, Clemence Mediavilla, Anne Vekhoff, Paul Coppo, Tounes Ledraa, Zora Marjanovic, Elise Corre, Simona Lapusan, Malek Aoudjhane, Ramdane Belhocine, Mohamad Mohty
Journal: Blood (2019)
Modified Conut Score Can Predict Prognosis in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Authors: Hajime Senjo, Masahiro Onozawa, Daisuke Hidaka, Shota Yokoyama, Satoshi Yamamoto, Yutaka Tsutsumi, Yoshihito Haseyama, Takahiro Nagashima, Akio Mori, Shuichi Ota, Hajime Sakai, Toshimichi Ishihara, Takuto Miyagishima, Yasutaka Kakinoki, Mitsutoshi Kurosawa, Hajime Kobayashi, Hiroshi Iwasaki, Takeshi Kondo, Takanori Teshima
Journal: Blood (2019)
RARE-50. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA – OUTCOMES IN THE ‘HAEMATOLOGY ERA’
Authors: Siddhant Kumar, Abdurrahman Islim, Jeffrey Smith, Brian Haylock, Aditya Shenoy, David Husband, Samantha Mills, Andrew Brodbelt, Emmanuel Chavredakis, David Lawson, Michael Jenkinson
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Primary CNS lymphoma (PCNSL) requires a biopsy for diagnosis. Administration of corticosteroids can lead to inconclusive results and delay diagnosis. The aim of this study was to compare outcomes of patients treated under haematology compared to radiation oncologists. METHODS Retrospective case review of patients treated under radiation oncology (2006–2010) and haematology (2011–2016). RESULTS 121 cases were identified (median age 63 years; range 19–84). Median WHO performance status (PS) was 1. Fourteen patients (11.6%) required repeat biopsy. 10 patients were managed palliatively due to poor PS. 67 cases were managed under haematology. Median symptom duration was 28 days (range 2–540). Median time from MRI to diagnosis was 18 days (range 6–232). 66 patients received chemotherapy, 1 received radiotherapy. Median overall survival (OS) was 8 months (95%CI:0.7–15.3), 5-year OS was 22.4%. 44 cases were managed under radiation oncology. Median symptom duration was 28 days (range 2–365). Median time from MRI to diagnosis was 16 days (range 6–309). 34 patients received radiotherapy first-line, 10 received chemotherapy. Median OS was 7 months (95%CI:0–21.5), 5-year OS was 15.9%. Multivariate analysis demonstrated PS (HR 2.02 (95%CI: 1.08–3.76)) and symptom duration (HR 0.63 (95%CI: 0.41–0.96)) to be significant prognostic indicators for OS. CONCLUSION The outcomes from the ‘haematology era’ are similar to those achieved by radiation oncologists. Delay in diagnosis leads to worse outcomes and highlights the ongoing need to streamline the patient pathway to improve outcomes.
Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis
Authors: Alexander G. Bick, James P. Pirruccello, Gabriel K. Griffin, Namrata Gupta, Stacey Gabriel, Danish Saleheen, Peter Libby, Sekar Kathiresan, Pradeep Natarajan
Journal: Circulation (2019)

Clonal hematopoiesis of indeterminate potential (CHIP) refers to clonal expansion of hematopoietic stem cells attributable to acquired leukemic mutations in genes such as
Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS
Authors: Brendan Rasor, Tyler Dickerson, Qiuhong Zhao, Jonathan E Brammer, Karilyn Larkin, Samantha Jaglowski, Alice S. Mims, Sam Penza, Sumithira Vasu, Sarah A Wall, Basem M. William, Ayman Saad, Julianna Roddy, Hannah K. Choe, Marcin Puto
Journal: Blood (2019)
Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
Authors: Carrie I Ho, Hatcher J. Ballard, W. Tris Arscott, Mitchell E. Hughes, Abigail Doucette, Daniel J. Landsburg, Sunita Dwivedy Nasta, James N. Gerson, Amit Maity, Stephen J. Schuster, Stefan K. Barta, John Plastaras, Jakub Svoboda
Journal: Blood (2019)
IMMU-45. CAR-T TREATMENT OF NOVEL MOUSE MODEL OF EGFRVIII+ GBM MIRRORS CLINICAL TRIAL OUTCOMES AND PROVIDES A SYNGENEIC PLATFORM FOR THE INVESTIGATION OF CAR-T MECHANISMS OF ACTION
Authors: Polly Chuntova, Akane Yamamichi, Ryosuke Naka, Yafei Hou, Hideho Okada
Journal: Neuro-Oncology (2019)

Abstract Despite the recent successes in cancer immunotherapy, brain tumors continue to present a significant challenge due to the unique relationship between the CNS and the immune system. Adoptive cell transfer of chimeric antigen receptor T-cells (CAR-T cells) targets tumor-associated and tumor-specific antigens. Multiple clinical trials testing CAR-T cells in the brain tumor setting have demonstrated the feasibility and safety, but also highlighted the limitations and continued need for treatment improvement. These challenges include recurrence of tumor cells that do not express the target antigens and induction of immuno-regulatory mechanisms, such as PD-L1 expression within the tumor. In this study, we used a murine GBM cell line (SB28), engineered to express the tumor-specific neoantigen human epidermal growth factor receptor variant III, to study the in vivo effects of EGFRvIII-CAR T-cells in a novel fully immunocompetent mouse model. SB28 cells have been shown to recapitulate key characteristics of human GBM, such as aggressive growth, low mutation burden, and resistance to immune checkpoint blockade therapy, and therefore, allow us to investigate many clinically relevant questions and variations in treatment protocol. Intravenous administration of CAR-transduced murine T-cells in EGFRvIII-expressing SB28 tumors showed survival benefit only when preceded by a lymphodepleting regimen. Despite prolonging survival, EGFRvIII-CAR-T cells were not curative, and the recurrent tumors displayed profound antigen loss, similar to post-treatment human tumor samples. Preliminary mechanistic studies revealed upregulation of IFNγ-inducible molecules, such as PD-L1 on tumor cells and tumor-infiltrating myeloid cells, as well as the emergence of a small, but discreet population of activated antigen presenting cells. Currently ongoing studies are aimed at delineating the exact molecular and cellular changes in the tumor microenvironment in response to the EGFRvIII-CAR T-cell treatment, in combination with clinically relevant therapies targeting the largely immunosuppressive tumor myeloid compartment
Mechanical Ventilation for Acute Respiratory Distress Syndrome during Extracorporeal Life Support. Research and Practice
Authors: Darryl Abrams, Matthieu Schmidt, Tài Pham, Jeremy R. Beitler, Eddy Fan, Ewan C. Goligher, James J. McNamee, Nicolò Patroniti, M. Elizabeth Wilcox, Alain Combes, Niall D. Ferguson, Danny F. McAuley, Antonio Pesenti, Michael Quintel, John Fraser, Carol L. Hodgson, Catherine L. Hough, Alain Mercat, Thomas Mueller, Vin Pellegrino, V. Marco Ranieri, Kathy Rowan, Kiran Shekar, Laurent Brochard, Daniel Brodie
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Section:ChooseTop of pageAbstract <<Conventional Approaches t...Rationale for Ultra–Lung-...Extracorporeal Membrane O...Optimizing Ventilator Set...Gas Exchange Targets duri...Additional Areas for Rese...ReferencesCITING ARTICLES
ANGI-05. ORIGIN OF MICROVASCULAR PROLIFERATION IN PILOCYTIC ASTROCYTOMA - MVP IN PILOCYTIC ASTROCYTOMA MIGHT PARTIALLY COMPRISE TUMOR-DERIVED CELLS
Authors: Shinji Yamashita, Hideo Takeshima, Takashi Watanabe, Kiyotaka Yokogami
Journal: Neuro-Oncology (2019)

Abstract Microvascular proliferation (MVP), an aberrant vascular structure containing multilayered mitotically active endothelial- and smooth-muscle cells/pericytes, is a histopathological hallmark of glioblastoma multiforme (GBM). Although MVP tends to be associated with high-grade glioma, it has also been detected in WHO grade I pilocytic astrocytoma (PA). However, little is known about the mechanism underlying its formation. Using TP53 point mutations as a marker for tumor-derived cells, we earlier reported that MVP was partially converted from tumor cells via mesenchymal transition. In the current study we used the KIAA1549-BRAF fusion gene as a marker to assess whether MVP in PA contained tumor-derived cells. cDNA synthesized from frozen tissue of six PA patients operated at our institute was analyzed to detect the KIAA1549-BRAF fusion gene by reverse transcription polymerase chain reaction (RT-PCR) assay. The breakpoint in the fusion gene was characterized by long and accurate PCR (LA-PCR) and Sanger sequencing of genomic DNA. Distinct tumor cells and cellular components of MVP were obtained by laser microdissection. For the qualitative and quantitative detection of the KIAA1549-BRAF fusion gene we performed genomic and digital PCR assays. Fluorescence in situ hybridization (FISH) was used to assess gene fusion in cellular components of MVP. Samples from three PA patients harbored the KIAA1549 exon 15, BRAF exon 9 fusion gene. In two patient samples with abundant MVP, RT-PCR assay detected strong bands arising from the KIAA1549-BRAF fusion gene in both tumor cells and cellular components of MVP. Digital PCR showed that vis-à-vis tumor tissue, its relative expression in cellular components of MVP was 42% in one- and 76% in another sample. FISH revealed amplified signals in both tumor cells and cellular components of MVP indicative of tandem duplication. Our findings suggest that in patients with PA, some cellular components of MVP may be tumor-derived.
VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
Authors: Katrina M Piedra, Hani Hassoun, Larry W. Buie, Sean M. Devlin, Jessica Flynn, Malin Hultcrantz, Alexander M. Lesokhin, Sydney X Lu, Sham Mailankody, Urvi A Shah, Eric L Smith, Ola Landgren, Neha Korde, Tim J Peterson
Journal: Blood (2019)